Impact of the admitting ward on care quality and outcomes in non-ST-segment elevation myocardial infarction: insights from a national registry.


Journal

European heart journal. Quality of care & clinical outcomes
ISSN: 2058-1742
Titre abrégé: Eur Heart J Qual Care Clin Outcomes
Pays: England
ID NLM: 101677796

Informations de publication

Date de publication:
05 Sep 2022
Historique:
received: 27 07 2021
revised: 23 08 2021
accepted: 02 09 2021
pubmed: 6 9 2021
medline: 9 9 2022
entrez: 5 9 2021
Statut: ppublish

Résumé

Little is known about the association between the type of admission ward and quality of care and outcomes for non-ST-segment elevation myocardial infarction (NSTEMI). We analysed data from 337 155 NSTEMI admissions between 2010 and 2017 in the UK Myocardial Ischaemia National Audit Project (MINAP) database. The cohort was dichotomised according to receipt of care either on a medical (n = 142,876) or cardiac ward, inclusive of acute cardiac wards and cardiac care unit (n = 194,279) on admission to hospital. Patients admitted to a cardiac ward were younger (median age 70 y vs. 75 y, P < 0.001), and less likely to be female (33% vs. 40%, P < 0.001). Independent factors associated with admission to a cardiac ward included ischaemic ECG changes (OR: 1.20, 95% CI: 1.18-1.23) and prior percutaneous coronary intervention (PCI) (OR: 1.19, 95% CI: 1.16-1.22). Patients admitted to a cardiac ward were more likely to receive optimal pharmacotherapy with statin (85% vs. 81%, P < 0.001) and dual antiplatelet therapy (DAPT) (91% vs. 88%, P < 0.001) on discharge, undergo invasive coronary angiography (78% vs. 59%, P < 0.001), and receive revascularisation in the form of PCI (52% vs. 36%, P < 0.001). Following multivariable logistic regression, the odds of inhospital all-cause mortality (OR: 0.75, 95% CI: 0.70-0.81) and major adverse cardiovascular events (MACE) (OR: 0.84, 95% CI: 0.78-0.91) were lower in patients admitted to a cardiac ward. Patients with NSTEMI admitted to a cardiac ward on admission were more likely to receive guideline directed management and had better clinical outcomes.

Identifiants

pubmed: 34482404
pii: 6364357
doi: 10.1093/ehjqcco/qcab062
pmc: PMC9442842
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

681-691

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

Références

PLoS One. 2018 Sep 4;13(9):e0203325
pubmed: 30180201
JAMA. 2004 Oct 6;292(13):1563-72
pubmed: 15467058
Nihon Rinsho. 2003 May;61 Suppl 5:444-50
pubmed: 12808982
Eur Heart J. 2007 Jun;28(12):1409-17
pubmed: 17412730
CMAJ. 2005 Jan 18;172(2):189-94
pubmed: 15655239
Open Heart. 2015 May 21;2(1):e000095
pubmed: 26019879
Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):557-567
pubmed: 33982094
Int J Cardiol. 2021 Apr 15;329:16-22
pubmed: 33388397
Eur Heart J Qual Care Clin Outcomes. 2022 Aug 17;8(5):518-528
pubmed: 33892502
J Am Coll Cardiol. 2000 Sep;36(3):959-69
pubmed: 10987628
Eur Heart J Acute Cardiovasc Care. 2017 Feb;6(1):34-59
pubmed: 27574334
JAMA. 2004 Jun 9;291(22):2727-33
pubmed: 15187054
Heart. 2021 May;107(9):734-740
pubmed: 33685933
Eur Heart J. 2020 Jan 1;41(1):12-85
pubmed: 31820000
Sociol Health Illn. 2018 Nov;40(8):1404-1429
pubmed: 29956339
Heart. 2010 Jul;96(14):1095-101
pubmed: 20511625
N Engl J Med. 1996 Dec 19;335(25):1880-7
pubmed: 8948564
Int J Cardiol. 2020 Feb 15;301:7-13
pubmed: 31810815
Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):323-331
pubmed: 32239140
Future Healthc J. 2020 Feb;7(1):78-83
pubmed: 32104771
Acute Card Care. 2009;11(3):173-80
pubmed: 19742351
Eur Heart J Qual Care Clin Outcomes. 2020 Jan 1;6(1):19-22
pubmed: 31511861
Heart. 2009 Oct;95(19):1593-9
pubmed: 19508971
Eur Heart J. 2017 Apr 1;38(13):974-982
pubmed: 28329279
BMJ Open. 2016 Jul 12;6(7):e011600
pubmed: 27406646
G Ital Cardiol (Rome). 2007 May;8(5 Suppl 1):5S-11S
pubmed: 17649867
Cochrane Database Syst Rev. 2020 Apr 23;4:CD000197
pubmed: 32324916

Auteurs

Saadiq M Moledina (SM)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, UK.

Ahmad Shoaib (A)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, UK.

Louise Y Sun (LY)

Division of Cardiac Anesthesiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Phyo K Myint (PK)

Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK.

Rafail A Kotronias (RA)

Division of Cardiovascular Medicine, BHF Centre of Research Excellence, University of Oxford, Oxford, UK.

Benoy N Shah (BN)

Department of Cardiology, Wessex Cardiac Centre, University Hospital Southampton, Southampton, UK.

Chris P Gale (CP)

Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.

Hude Quan (H)

Centre for Health Informatics, University of Calgary, Calgary, Alberta, Canada.

Rodrigo Bagur (R)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, UK.

Mamas A Mamas (MA)

Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH